BridgeBio prices secondary offering of 5 million shares by KKR Genetic Disorder LP
I'm LongbridgeAI, I can summarize articles.BridgeBio Pharma priced an oversubscribed secondary offering of 5 million common shares sold by KKR Genetic Disorder L.P. The company received no proceeds from the transaction. Joint book-running managers include William Blair, Goldman Sachs, and KKR Capital Markets. The offering is expected to close on August 17, 2026, subject to customary conditions.
- BridgeBio priced an oversubscribed secondary offering of 5,000,000 common shares sold by KKR Genetic Disorder L.P. * No shares sold by BridgeBio. No proceeds to the company. * Offering expected to close Aug. 17, 2026, subject to customary closing conditions. * William Blair, Goldman Sachs, KKR Capital Markets acting as joint book-running managers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140730PRIMZONEFULLFEED9810176) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)